The electrocompetent cells are the bacterial cells which are sufficiently permeable to allow external DNA entry upon application of an electric field. These cells found widespread applications across biotechnology and pharmaceutical industries for research activities such as plasmid DNA transformation and cloning of desired genes. The advantages of electrocompetent cells include efficient uptake of DNA, higher transformation efficiency, and elimination of need for heat-shock treatment during transformation process.
The global Electrocompetent Cells Market is estimated to be valued at US$ 2.07 Bn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growing demand for electrocompetent cells from biotechnology and pharmaceutical industries is one of the major factors fueling the market growth. Electrocompetent cells find major applications in cloning, protein production, whole-genome sequencing, DNA library preparation, and mutagenesis studies conducted by various biotech and pharma companies. With increasing R&D investments in drug discovery and development of novel biologics, the demand for cloning and expression of desired genes is growing significantly. This in turn is boosting the adoption of electrocompetent cells as they offer high transformation efficiency and simplified transformation protocols. Moreover, escalating demand for plasmid DNA, which acts as an intermediate in production of various biologics like monoclonal antibodies, vaccines, and recombinant proteins, is also augmenting the electrocompetent cells market.
SWOT Analysis
Strength: Electrocompetent cells offer convenience and consistency in transforming cells with external DNA. They enhance the efficiency of DNA cloning and reduce overall experiment time and cost.
Weakness: The transformation efficiency of electrocompetent cells can vary significantly depending on cell strain and manufacturer. Improper preparation and storage of cells negatively impacts transformation efficiency.
Opportunity: Growing research activities in synthetic biology and genome engineering is driving demand for advanced cloning techniques. Rising focus on reducing procedure timelines in life science research also presents an opportunity.
Threats: Stringent regulations pertaining to genetic modification may limit the application scope of electrocompetent cells. Budget constraints faced by research organizations also poses a threat to market growth.
Key Takeaways
The global electrocompetent cells market is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to reach US$ 2.07 Bn by 2024, growing at a CAGR of around 10%.
Regional analysis
North America dominates the global market and is expected to maintain its lead through 2030. This can be attributed to extensive research funding and presence of major players. The Asia Pacific region is projected to witness the fastest growth supported by increasing R&D expenditure and expanding biotechnology sector in countries like China and India.
Key players
Key players operating in the electrocompetent cells market are Merck KGaA, Thermo Fisher Scientific, Agilent Technologies, Takara Bio, Promega Corporation, Beijing TransGen Biotech, GeneScript Corporation, Yeastern Biotech, New England Biolabs, and Bio-Rad Laboratories.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
